Tumor Necrosis Factor Ligand Superfamily Member 15, active (TNFSF15), Recombinant, Human

Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis. {ECO:0000269, PubMed:10597252, ECO:0000269, PubMed:11911831, ECO:0000269, PubMed:11923219, ECO:0000269, PubMed:9872942}. Biological Activity: Fully biologically active when compared to standard. The ED50 as determined by its ability to induce apoptosis using human TF-1 cells is less than 20ng/ml, corresponding to a specific activity of ? 5.0x10e4 IU/mg. Sequence: LKGQEFAPSH QQVYAPLRAD GDKPRAHLTV VRQTPTQHFK NQFPALHWEH ELGLAFTKNR MNYTNKFLLI PESGDYFIYS QVTFRGMTSE CSEIRQAGRP NKPDSITVVI TKVTDSYPEP TQLLMGTKSV CEVGSNWFQP IYLGAMFSLQ EGDKLMVNVS DISLVDYTKE DKTFFGAFLL, Molecular Weight: 20.5kD, PubMed ID: 9872942, 11923219, 11911831, 14702039, 15164053, 15489334, 9434163, 10597252, 17935696, 21300286, Gene Name: TNFSF15,TL1,VEGI, Swiss Prot: O95150, Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.